KRAS (GTPase KRas) variants and mutations
KRAS (also known as GTPase KRas) is a human protein-coding gene encoding a GTPase protein. A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer. This analysis covers 825 KRAS variants and mutations. Of these, 41% have computational variant effect predictions. Disease context includes Noonan syndrome, Noonan syndrome 3, and cardiofaciocutaneous syndrome 2. Example KRAS variants include M1*, T2P, and T2S.
Variant analysis overview
- Gene: KRAS
- Protein: GTPase KRas
- UniProt accession: P01116
- Organism: Homo sapiens
- Variants analyzed: 825
- Variant scope: all variants
- Completed: 2026-07-23
Variant and mutation evidence
- Variant composition: 685 unspecified-consequence records; 2 natural variant; 43 missense variants; 9 frameshift variants; 66 synonymous variants; 4 in-frame deletions; 2 stop-gained variants; 2 stop retained variant; 2 stop lost; 1 splice-region variants; 9 substitution
- Prediction scores: 341 variants have prediction scores (41% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Noonan syndrome, Noonan syndrome 3, cardiofaciocutaneous syndrome 2, cardiofaciocutaneous syndrome, non-small cell lung carcinoma, gastric cancer, acute myeloid leukemia, linear nevus sebaceous syndrome, Toriello-Lacassie-Droste syndrome, Linear nevus sebaceus syndrome, RAS-associated autoimmune leukoproliferative disease, autoimmune lymphoproliferative syndrome type 4.
Protein structure and variant hotspots
- Protein features: 17 binding sites; 5 post-translational modification sites.
- PTM context: 18 variants overlap post-translational modification sites.
- Experimental data: 186 protein positions have experimental scores. Source: binding assays, abundance assays.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KRAS variants
Examples include M1*, T2P, T2S, E3D, E3K, E3G, Y4*, Y4F. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1* (p.Met1Ter), rs2548933434, ClinGen CA2580085338, ClinVar RCV002292294, Uncertain significance
- T2P (p.Thr2Pro), rs2135806400, ClinGen CA384157599, ClinVar RCV002343026, AlphaMissense 0.34, MetaLR 0.65, Uncertain significance, Cardiovascular phenotype
- T2S (p.Thr2Ser), Ensembl rs2135806400, Uncertain significance, Prostate cancer, hereditary, 1
- E3D (p.Glu3Asp), Ensembl rs2135806390
- E3K (p.Glu3Lys), NCI-TCGA Cosmic COSV5609, NCI-TCGA Cosmic COSV9977, cosmic curated COSV99771, Variant assessed as somatic; moderate impact.
- E3G (p.Glu3Gly), rs890056388, []
- Y4* (p.Tyr4Ter), rs2548933405, ClinGen CA384157539, ClinVar RCV002292291, Uncertain significance
- Y4F (p.Tyr4Phe), rs2548933406, ClinGen CA384157542, ClinVar RCV002292288, Uncertain significance, Prostate cancer, hereditary, 1
- Y4N (p.Tyr4Asn), rs2548933409, ClinGen CA384157561, ClinVar RCV002292315, Uncertain significance, Prostate cancer, hereditary, 1
- K5* (p.Lys5Ter), rs193929331, ClinGen CA384157535, ClinVar RCV002292292, AlphaMissense 0.99, MetaLR 0.84, Uncertain significance, in GASC
- K5E (p.Lys5Glu), rs193929331, ClinGen CA250291, NCI-TCGA Cosmic COSV5550, cosmic curated COSV55502, REVEL 0.89, AlphaMissense 0.99, Pathogenic/Likely pathogenic, KRAS-related disorder; not provided; RASopathy
- K5I (p.Lys5Ile), Ensembl rs2135806379
- K5N (p.Lys5Asn), rs104894361, ClinGen CA16042877, cosmic curated COSV56027, ClinVar RCV000413067, AlphaMissense 1.00, MetaLR 0.73, Pathogenic, RASopathy
- K5Q (p.Lys5Gln), rs193929331, ClinGen CA384157537, ClinVar RCV002833819, AlphaMissense 0.99, MetaLR 0.84, Likely pathogenic, RASopathy
- L6F (p.Leu6Phe), rs1296330213, ClinGen CA384157517, ClinVar RCV002292293, AlphaMissense 0.41, MetaLR 0.40, Uncertain significance, Prostate cancer, hereditary, 1
- L6I (p.Leu6Ile), gnomAD rs1296330213, Uncertain significance
- L6P (p.Leu6Pro), Ensembl rs2135806364
- L6V (p.Leu6Val), rs1296330213, ClinGen CA384157518, ClinVar RCV001341946, gnomAD rs1296330213, REVEL 0.49, AlphaMissense 0.41, Uncertain significance, RASopathy
- V7E (p.Val7Glu), rs2135806346, ClinGen CA384157507, ClinVar RCV003230833, Ensembl rs2135806346, AlphaMissense 1.00, MetaLR 0.84, Likely pathogenic, RASopathy
- V7L (p.Val7Leu), Ensembl rs2135806349, Uncertain significance
- V7M (p.Val7Met), rs2135806349, ClinGen CA384157511, cosmic curated COSV56130, ClinVar RCV001355312, AlphaMissense 0.99, MetaLR 0.67, Uncertain significance, not provided
- V8I (p.Val8Ile), rs2135806332, ClinGen CA384157501, cosmic curated COSV55592, ClinVar RCV001355366, AlphaMissense 0.51, MetaLR 0.48, Uncertain significance, not provided
- V8L (p.Val8Leu), Ensembl rs2135806332, Uncertain significance, Neoplasm
- V9A (p.Val9Ala), Ensembl rs2135806320, Uncertain significance, Cardiovascular phenotype
- V9G (p.Val9Gly), Ensembl rs2135806320
- V9I (p.Val9Ile), cosmic curated COSV55798, Ensembl rs1951664416
- V9L (p.Val9Leu), Ensembl rs1951664416
- G10* (p.Gly10Ter), Ensembl rs2135806313
- G10A (p.Gly10Ala), Ensembl rs2135806301
- G10V (p.Gly10Val), cosmic curated COSV55508, Ensembl rs2135806301
- G10R (p.Gly10Arg), Ensembl rs2135806313, cosmic curated COSV55525
- A11G (p.Ala11Gly), cosmic curated COSV10584, Ensembl rs2135806273
- A11S (p.Ala11Ser), rs2548933346, ClinGen CA384157468, ClinVar RCV002292303, Uncertain significance, Prostate cancer, hereditary, 1
- A11V (p.Ala11Val), cosmic curated COSV55802, Ensembl rs2135806273
- G12A (p.Gly12Ala), rs121913529, ClinGen CA135567, cosmic curated COSV55497, ClinVar RCV000038266, REVEL 0.84, MetaLR 0.57, Pathogenic/Likely pathogenic, Familial cancer of breast; Autoimmune lymphoproliferative syndrome type 4; Cardi
- G12C (p.Gly12Cys), rs121913530, ClinGen CA122528, cosmic curated COSV55497, ClinVar RCV000013406, AlphaMissense 1.00, MetaLR 0.70, Pathogenic, not provided
- G12D (p.Gly12Asp), rs121913529, Civic 79, ClinGen CA122538, cosmic curated COSV55497, REVEL 0.88, MetaLR 0.58, Pathogenic/Likely pathogenic, Lung cancer; Malignant tumor of urinary bladder; Cerebral arteriovenous malforma
- G12R (p.Gly12Arg), rs121913530, ClinGen CA122531, cosmic curated COSV55497, ClinVar RCV000013407, AlphaMissense 1.00, MetaLR 0.70, Pathogenic/Likely pathogenic, not provided; RASopathy
- G12S (p.Gly12Ser), rs121913530, ClinGen CA135565, cosmic curated COSV55497, ClinVar RCV000013414, REVEL 0.79, AlphaMissense 1.00, Pathogenic, Vascular malformation; Cardiofaciocutaneous syndrome 2; not provided
- G12V (p.Gly12Val), rs121913529, ClinGen CA122540, cosmic curated COSV55497, ClinVar RCV000013413, REVEL 0.91, MetaLR 0.70, Pathogenic, not provided; RASopathy; Linear nevus sebaceous syndrome
- G13A (p.Gly13Ala), cosmic curated COSV55497, gnomAD rs112445441, Pathogenic, in pylocytic astrocytoma
- G13C (p.Gly13Cys), rs121913535, ClinGen CA135570, cosmic curated COSV55497, ClinVar RCV000038268, AlphaMissense 1.00, MetaLR 0.77, Pathogenic/Likely pathogenic, KRAS-related disorder; Autoimmune lymphoproliferative syndrome type 4; not provi
- G13D (p.Gly13Asp), rs112445441, ClinGen CA122534, NCI-TCGA Cosmic COSV5549, REVEL 0.83, AlphaMissense 0.96, Pathogenic, Noonan syndrome and Noonan-related syndrome; Inborn genetic diseases; Familial p
- G13R (p.Gly13Arg), Ensembl rs2135806161, Pathogenic, not provided
- G13S (p.Gly13Ser), cosmic curated COSV55509, gnomAD rs121913535, Pathogenic, in pylocytic astrocytoma
- G13V (p.Gly13Val), rs112445441, ClinGen CA135573, NCI-TCGA Cosmic COSV5549, AlphaMissense 0.96, MetaLR 0.51, Pathogenic, Non-small cell lung carcinoma
- V14E (p.Val14Glu), Ensembl rs2135806110
- V14G (p.Val14Gly), cosmic curated COSV55520, Ensembl rs2135806110
- V14I (p.Val14Ile), rs104894365, ClinGen CA156358, NCI-TCGA Cosmic COSV5550, cosmic curated COSV55501, REVEL 0.80, MetaLR 0.82, Pathogenic, RASopathy
- V14L (p.Val14Leu), cosmic curated COSV10880, ExAC rs104894365, gnomAD rs104894365, Pathogenic, in NS3
- G15A (p.Gly15Ala), Ensembl rs1555195579, Likely pathogenic
- G15C (p.Gly15Cys), rs2135806091, ClinGen CA384157446, ClinVar RCV002292307, AlphaMissense 1.00, MetaLR 0.99, Uncertain significance, Prostate cancer, hereditary, 1
- G15D (p.Gly15Asp), cosmic curated COSV55685, Ensembl rs1555195579, Likely pathogenic
- G15R (p.Gly15Arg), Ensembl rs2135806091
- G15S (p.Gly15Ser), cosmic curated COSV55865, Ensembl rs2135806091
- G15V (p.Gly15Val), rs1555195579, ClinGen CA384157440, ClinVar RCV000521534, Ensembl rs1555195579, REVEL 0.96, MetaLR 0.99, Likely pathogenic, not provided
- K16N (p.Lys16Asn), Ensembl rs2135806070
- S17I (p.Ser17Ile), rs1951663808, ClinGen CA384157419, ClinVar RCV002292309, AlphaMissense 0.68, MetaLR 0.44, Uncertain significance, Prostate cancer, hereditary, 1
- S17N (p.Ser17Asn), cosmic curated COSV56109, TOPMed rs1951663808
- S17R (p.Ser17Arg), ExAC rs776785730, gnomAD rs776785730
- S17T (p.Ser17Thr), cosmic curated COSV99782, TOPMed rs1951663808, Uncertain significance, Vascular malformation
- A18D (p.Ala18Asp), NCI-TCGA Cosmic COSV5556, NCI-TCGA Cosmic COSV5558, cosmic curated COSV55580, NCI-TCGA Cosmic COSV5571, REVEL 0.88, MetaLR 0.80, Variant assessed as somatic; moderate impact.
- A18G (p.Ala18Gly), cosmic curated COSV55715, Ensembl rs2135806030, Pathogenic
- A18P (p.Ala18Pro), Ensembl rs2135806040
- A18T (p.Ala18Thr), cosmic curated COSV56195, Ensembl rs2135806040
- A18V (p.Ala18Val), rs2135806030, ClinGen CA384157405, cosmic curated COSV55561, ClinVar RCV002264903, AlphaMissense 0.97, MetaLR 0.75, Pathogenic, Noonan syndrome 3
- L19F (p.Leu19Phe), rs121913538, ClinGen CA16602501, cosmic curated COSV55502, ClinVar RCV001354208, REVEL 0.80, MetaLR 0.82, Likely pathogenic, not provided
- L19M (p.Leu19Met), ExAC rs771188508, gnomAD rs771188508
- T20A (p.Thr20Ala), rs2135806003, ClinGen CA384157392, ClinVar RCV001420539, Ensembl rs2135806003, AlphaMissense 0.96, MetaLR 0.56, Uncertain significance, Cardiofaciocutaneous syndrome 2
- T20M (p.Thr20Met), cosmic curated COSV55571, Ensembl rs2135805997, REVEL 0.84, MetaLR 0.64, Likely pathogenic, not provided
- T20R (p.Thr20Arg), NCI-TCGA Cosmic COSV5557, NCI-TCGA Cosmic COSV5588, cosmic curated COSV55887, Ensembl rs2135805997, Variant assessed as somatic; moderate impact.
- T20S (p.Thr20Ser), cosmic curated COSV56032, Ensembl rs2135806003, Uncertain significance
- I21K (p.Ile21Lys), rs2135805981, ClinGen CA384157379, ClinVar RCV002292311, AlphaMissense 1.00, MetaLR 0.53, Uncertain significance, Prostate cancer, hereditary, 1
- I21L (p.Ile21Leu), Ensembl rs2135805986
- I21R (p.Ile21Arg), NCI-TCGA Cosmic COSV1043, NCI-TCGA Cosmic COSV5570, cosmic curated COSV55705, Ensembl rs2135805981, Variant assessed as somatic; moderate impact.
- Q22* (p.Gln22Ter), Civic 479, cosmic curated COSV55779, Ensembl rs121913236, Pathogenic, in NS3
- Q22E (p.Gln22Glu), rs121913236, ClinGen CA384157372, ClinVar RCV000654936, UniProt VAR 064850, REVEL 0.82, MetaLR 0.71, Pathogenic, RASopathy
- Q22H (p.Gln22His), gnomAD rs1951663491, cosmic curated COSV56181, Likely benign, in NS3
- Q22K (p.Gln22Lys), rs121913236, ClinGen CA16602771, NCI-TCGA Cosmic COSV5552, cosmic curated COSV55526, REVEL 0.81, MetaLR 0.69, Pathogenic/Likely pathogenic, Vascular malformation; not provided; RASopathy
- Q22L (p.Gln22Leu), rs727503110, ClinGen CA296089, cosmic curated COSV55758, ClinVar RCV000157947, AlphaMissense 0.98, MetaLR 0.72, Likely pathogenic, not provided
- Q22P (p.Gln22Pro), rs727503110, ClinGen CA384157368, ClinVar RCV002292312, AlphaMissense 0.98, MetaLR 0.72, Uncertain significance, Prostate cancer, hereditary, 1
- Q22R (p.Gln22Arg), rs727503110, ClinGen CA235299, cosmic curated COSV55525, ClinVar RCV000150893, AlphaMissense 0.98, MetaLR 0.72, Pathogenic, RASopathy
- L23Q (p.Leu23Gln), Ensembl rs730880472, Likely pathogenic
- L23R (p.Leu23Arg), rs730880472, ClinGen CA296092, NCI-TCGA Cosmic COSV5553, cosmic curated COSV55534, AlphaMissense 0.99, MetaLR 0.70, Conflicting interpretations, not provided
- L23V (p.Leu23Val), Ensembl rs2135805957
- I24F (p.Ile24Phe), Ensembl rs2135805949
- I24N (p.Ile24Asn), NCI-TCGA Cosmic COSV5551, cosmic curated COSV55516, Ensembl rs2135805942, Variant assessed as somatic; moderate impact.
- Q25* (p.Gln25Ter), cosmic curated COSV55598, Ensembl rs1951663379
- Q25E (p.Gln25Glu), Ensembl rs1951663379
- Q25H (p.Gln25His), cosmic curated COSV56064, Ensembl rs2135805909, Uncertain significance
- Q25L (p.Gln25Leu), rs2135805919, ClinGen CA384157339, ClinVar RCV002292316, AlphaMissense 0.93, MetaLR 0.46, Uncertain significance, Prostate cancer, hereditary, 1
- Q25R (p.Gln25Arg), rs2135805919, ClinGen CA384157340, ClinVar RCV001358141, Ensembl rs2135805919, REVEL 0.69, AlphaMissense 0.93, Uncertain significance, not provided
- N26H (p.Asn26His), rs794727277, ClinGen CA384157332, ClinVar RCV001808080, Ensembl rs794727277, AlphaMissense 0.84, MetaLR 0.75, Uncertain significance, Noonan syndrome 3
- N26I (p.Asn26Ile), cosmic curated COSV99784, Ensembl rs2135805894
- N26K (p.Asn26Lys), Ensembl rs2135805889
- N26R (p.Asn26Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- N26T (p.Asn26Thr), rs2135805894, ClinGen CA384157328, ClinVar RCV002292318, AlphaMissense 0.99, MetaLR 0.68, Uncertain significance, Prostate cancer, hereditary, 1
- N26Y (p.Asn26Tyr), rs794727277, ClinGen CA241569, cosmic curated COSV56197, ClinVar RCV000175794, REVEL 0.85, AlphaMissense 0.84, Uncertain significance, not provided; RASopathy
- H27D (p.His27Asp), Ensembl rs2135805878
- H27L (p.His27Leu), rs2135805862, ClinGen CA384157316, cosmic curated COSV56220, ClinVar RCV002292320, AlphaMissense 0.73, MetaLR 0.26, Uncertain significance, Prostate cancer, hereditary, 1
- H27R (p.His27Arg), rs2135805862, ClinGen CA384157317, ClinVar RCV002292319, AlphaMissense 0.73, MetaLR 0.26, Uncertain significance, Prostate cancer, hereditary, 1
- H27Y (p.His27Tyr), cosmic curated COSV55635, Ensembl rs2135805878
- F28L (p.Phe28Leu), rs2548933172, ClinGen CA384157303, ClinVar RCV002292322, Uncertain significance, Prostate cancer, hereditary, 1
- V29E (p.Val29Glu), Ensembl rs2135805859
- D30E (p.Asp30Glu), rs113623140, ClinGen CA384157278, cosmic curated COSV55881, ClinVar RCV002292324, AlphaMissense 0.48, MetaLR 0.11, Uncertain significance, Prostate cancer, hereditary, 1
- D30H (p.Asp30His), Ensembl rs2135805846
- D30N (p.Asp30Asn), NCI-TCGA TCGA novel, Ensembl rs2135805846, Variant assessed as somatic; moderate impact.
- D30Y (p.Asp30Tyr), Ensembl rs2135805846
- E31* (p.Glu31Ter), rs2135805818, ClinGen CA384157274, ClinVar RCV002292326, AlphaMissense 0.90, MetaLR 0.52, Uncertain significance
- E31K (p.Glu31Lys), cosmic curated COSV55520, Ensembl rs2135805818
- E31Q (p.Glu31Gln), cosmic curated COSV55980, Ensembl rs2135805818
- Y32* (p.Tyr32Ter), Ensembl rs2135805795
- Y32D (p.Tyr32Asp), Ensembl rs2135805801
- Y32N (p.Tyr32Asn), Ensembl rs2135805801
- Y32S (p.Tyr32Ser), rs2548933141, ClinGen CA384157261, ClinVar RCV002292327, Uncertain significance, Prostate cancer, hereditary, 1
- D33E (p.Asp33Glu), NCI-TCGA Cosmic COSV5552, cosmic curated COSV55525, NCI-TCGA Cosmic COSV5581, Ensembl rs2135805765, REVEL 0.54, MetaLR 0.40, Variant assessed as somatic; moderate impact.
- D33G (p.Asp33Gly), rs2135805772, ClinGen CA384157247, ClinVar RCV003237173, ClinVar RCV003655413, AlphaMissense 1.00, MetaLR 0.60, Uncertain significance, not provided; RASopathy
- D33H (p.Asp33His), Ensembl rs2135805778
- D33N (p.Asp33Asn), cosmic curated COSV10730, Ensembl rs2135805778
- D33V (p.Asp33Val), Ensembl rs2135805772
- D33Y (p.Asp33Tyr), Ensembl rs2135805778, REVEL 0.85, MetaLR 0.68
- P34A (p.Pro34Ala), Ensembl rs2135805755
- P34L (p.Pro34Leu), rs104894366, ClinGen CA235301, NCI-TCGA Cosmic COSV5558, AlphaMissense 1.00, MetaLR 0.82, Pathogenic, Noonan syndrome
- P34Q (p.Pro34Gln), rs104894366, ClinGen CA384157234, cosmic curated COSV55580, ClinVar RCV004550646, AlphaMissense 1.00, MetaLR 0.82, Likely pathogenic, KRAS-related disorder
- P34R (p.Pro34Arg), rs104894366, ClinGen CA280040, NCI-TCGA Cosmic COSV5558, AlphaMissense 1.00, MetaLR 0.82, Pathogenic/Likely pathogenic, Noonan syndrome 3; Acute myeloid leukemia; Cardiofaciocutaneous syndrome 2
- P34S (p.Pro34Ser), cosmic curated COSV55745, Ensembl rs2135805755
- P34T (p.Pro34Thr), NCI-TCGA Cosmic COSV5573, cosmic curated COSV55736, NCI-TCGA Cosmic COSV5574, Ensembl rs2135805755, Variant assessed as somatic; moderate impact., in CFC2
- T35A (p.Thr35Ala), cosmic curated COSV55950, Ensembl rs2135805739
- T35K (p.Thr35Lys), Ensembl rs2135805733
- T35R (p.Thr35Arg), Ensembl rs2135805733
- I36K (p.Ile36Lys), rs2135805713, ClinGen CA384157219, ClinVar RCV002292263, Ensembl rs2135805713, AlphaMissense 1.00, MetaLR 0.80, Uncertain significance, Prostate cancer, hereditary, 1
- I36M (p.Ile36Met), rs727503109, ClinGen CA273162, NCI-TCGA Cosmic COSV5572, cosmic curated COSV55721, AlphaMissense 0.99, MetaLR 0.77, Pathogenic/Likely pathogenic, Cardiovascular phenotype; Noonan syndrome; Cardio-facio-cutaneous syndrome
- I36V (p.Ile36Val), rs2135805722, ClinGen CA384157222, ClinVar RCV003233234, Ensembl rs2135805722, AlphaMissense 0.84, MetaLR 0.48, Uncertain significance, not provided
- E37* (p.Glu37Ter), rs2135805697, ClinGen CA384157210, ClinVar RCV002292295, AlphaMissense 1.00, MetaLR 0.69, Uncertain significance
- E37D (p.Glu37Asp), Ensembl rs2135805691
- E37K (p.Glu37Lys), cosmic curated COSV55573, Ensembl rs2135805697
- E37Q (p.Glu37Gln), Ensembl rs2135805697
- E37E (p.Glu37Glu), rs1592808357, gnomAD 12-25227335-C-T, AlphaMissense 0.97, MetaLR 0.31
- D38E (p.Asp38Glu), Ensembl rs2141510577
- D38H (p.Asp38His), Ensembl rs2141510590
- D38N (p.Asp38Asn), cosmic curated COSV55688, Ensembl rs2141510590, Uncertain significance, RASopathy
- D38V (p.Asp38Val), Ensembl rs2141510582
- D38Y (p.Asp38Tyr), cosmic curated COSV99788, Ensembl rs2141510590
- S39C (p.Ser39Cys), Ensembl rs2141510561
- S39F (p.Ser39Phe), Ensembl rs2141510561
- S39T (p.Ser39Thr), Ensembl rs2141510572
- S39S (p.Ser39Ser), rs2141510554, gnomAD 12-25227407-G-A, CADD 11.20
- S39I (p.Ser39Ile), gnomAD 12-25235213-C-A, CADD 0.61, SIFT 0.00
- S39G (p.Ser39Gly), gnomAD 12-25235214-T-C, CADD 0.62, SIFT 0.00
- S39K (p.Ser39Lys), rs765963191, gnomAD 12-25235216-C-CT, CADD 5.17
- S39N (p.Ser39Asn), gnomAD 12-25235216-C-T, CADD 1.25, SIFT 0.43
- S39A (p.Ser39Ala), gnomAD 12-25235216-CT-C, CADD 4.63
- Y40* (p.Tyr40Ter), Ensembl rs2141510540
- Y40C (p.Tyr40Cys), NCI-TCGA TCGA novel, Uncertain significance, RASopathy
- Y40H (p.Tyr40His), Ensembl rs2141510546
- R41G (p.Arg41Gly), rs2548920719, ClinGen CA384152476, ClinVar RCV003154520, Uncertain significance, not provided
- R41S (p.Arg41Ser), Ensembl rs2141510521, REVEL 0.60, MetaLR 0.47
- R41T (p.Arg41Thr), Ensembl rs2141510533
- R41Q (p.Arg41Gln), rs934770901, []
- K42N (p.Lys42Asn), Ensembl rs2141510517, Likely benign
- Q43* (p.Gln43Ter), Ensembl rs2141510513
- Q43E (p.Gln43Glu), Ensembl rs2141510513
- Q43L (p.Gln43Leu), Ensembl rs2141510506
- Q43H (p.Gln43His), gnomAD 12-25227395-T-G, REVEL 0.45, MetaLR 0.34
- V44A (p.Val44Ala), Ensembl rs2141510488
- V44E (p.Val44Glu), cosmic curated COSV55751, Ensembl rs2141510488
- V44G (p.Val44Gly), Ensembl rs2141510488
- V44I (p.Val44Ile), cosmic curated COSV55926, Ensembl rs2141510495, REVEL 0.26, MetaLR 0.33
- V44L (p.Val44Leu), Ensembl rs2141510495
- V44V (p.Val44Val), rs2141510481, gnomAD 12-25227392-T-C, CADD 12.00, SIFT 0.02
- V45E (p.Val45Glu), Ensembl rs2141510470
- V45L (p.Val45Leu), Ensembl rs2141510473
- V45V (p.Val45Val), rs1951407606, gnomAD 12-25227389-T-C, CADD 11.30, SIFT 1.00
- I46L (p.Ile46Leu), Ensembl rs2141510457
- I46M (p.Ile46Met), TOPMed rs904755552, Uncertain significance, RASopathy
- I46V (p.Ile46Val), rs2141510457, ClinGen CA384152393, ClinVar RCV003654672, REVEL 0.30, MetaLR 0.16, Uncertain significance, RASopathy
- D47G (p.Asp47Gly), rs1565885006, ClinGen CA384152371, ClinVar RCV000781489, Ensembl rs1565885006, AlphaMissense 0.94, MetaLR 0.61, Uncertain significance, not specified
- D47H (p.Asp47His), Ensembl rs2141510444
- D47N (p.Asp47Asn), Ensembl rs2141510444
- D47V (p.Asp47Val), Ensembl rs1565885006, Uncertain significance
Public KRAS analysis runs
- KRAS analysis run — KRAS (825 variants) — completed 2026-07-23